Lake Placid, Florida (PRWEB) June 11, 2012
According to a recent story posted by The Wall Street Journal, Cytomedix, Inc. has been approved for phase two of its testing of a new, adult stem cell treatment for post-acute ischemic stroke. The Data Safety Monitoring Board (DSMB) has recommended that the trial be expanded from its current three clinical sites to a total of 15 clinical sites. Dr. Rachna Mehra, who specializes in adult stem cell treatment, believes that the successes achieved by this and similar studies will pave the way for the future of the medical industry.
According to the aforementioned press release, the trials are double-blind and placebo-controlled. Each trial tests the success of ALD-401 with regard to 100 participants, each of which has suffered from unilateral, cerebral ischemic stroke. The strokes experienced by participants must rank between seven and 22 on the NIH stroke scale when the medication is administered. Additionally, the medication must be taken between 13 and 19 days after the ischemic stroke has occurred.
According to Martin Rosendale, Chief Executive Officer, "We are very encouraged by the decision of the DSMB to recommend the continuation of the RECOVER-Stroke trial and look forward to expanding this important trial to additional leading stroke clinical sites across the U.S. [...] Preclinical research with ALD-401 has shown improvements in motor function, in mitigation of the decrease in brain volume, the reversal of decline in stroke-induced cell viability, and improved blood flow in the brain. We are hopeful that ALD-401 will continue to demonstrate these regenerative activities in this trial and look forward to advancing its clinical development."
ALD-401 is created with the use of adult stem cells gathered from bone marrow, which are harvested from the patient who is receiving the medication. Dr. Rachna Mehra believes this innovative use of adult stem cells to be a promising step forward in the medical field. She is a strong proponent of Platelet Rich Plasma techniques regarding adult stem cell treatment, and she understands the benefits that these treatment techniques can offer.
"I sincerely believe this is the future of health care," commented Dr. Rachna Mehra. "We have already been very successful in using Platelet Rich Plasma Stem Cell protocol in the treatment of osteoarthritis and sports injury related issues, and promising outcomes of research in various other conditions, such as stroke and heart failure, are very encouraging."
Dr. Rachna Mehra is a highly regarded professional interested in adult stem cell treatment, including Platelet Rich Plasma and Prolotherapy. Dr. Rachna Mehra also provides services regarding bio-identical hormones, hormone replacement therapy, Botox, and nutrition. To learn more about her practice, visit http://www.drrachna.com.